After announcing back in late June that Novartis would be spinning off Alcon, the eye care division of Novartis, has now announced plans to locate its future global headquarters in the Canton of Geneva, Switzerland, following completion of the proposed spinoff. Alcon corporate and EMEA employees will begin moving to the new location in 2019.
Alcon's new headquarters will be the primary location for Alcon's senior corporate leadership and other corporate and commercial functions.
While final details are being finalized, Alcon could employ up to 700 in Switzerland post spin-off. Alcon's current global divisional headquarters in Fort Worth, Texas, will remain operational, commercial and innovation hub for the proposed standalone company.
"We are delighted to announce Geneva as the location of Alcon's new global headquarters following the proposed spinoff from Novartis," said David Endicott, CEO of Alcon. "For more than 40 years, Alcon has had a significant presence in Switzerland, which is known for its progressive business climate and innovation-friendly policies. Being headquartered in Geneva will help further increase Alcon's global scale and reach to better serve our customers."
Read the full release here